The Observed Variance Between Predicted and Measured Radiation Dose in Breast and Prostate Patients Utilizing an In Vivo Dosimeter

Sicel Technologies Inc., Morrisville, NC, USA.
International Journal of Radiation OncologyBiologyPhysics (Impact Factor: 4.18). 11/2008; 72(2):597-604. DOI: 10.1016/j.ijrobp.2008.05.058
Source: PubMed

ABSTRACT Report the results of using a permanently implantable dosimeter in radiation therapy: determine specific adverse events, degree of migration, and acquire dose measurements during treatment to determine difference between expected and measured dose.
The Dose Verification System is a wireless, permanently implantable metal-oxide semiconductor field-effect transistor dosimeter using a bidirectional antenna for power and data transfer. The study cohort includes 36 breast (33 patients received two devices) and 29 prostate (21 patients received two devices) cancer patients. A total of 1,783 and 1,749 daily dose measurements were obtained on breast and prostate patients, respectively. The measurements were compared with the planned expected dose. Biweekly computed tomography scans were obtained to evaluate migration and the National Cancer Institute's Common Toxicity Criteria, version 3, was used to evaluate adverse events.
Only Grade I/II adverse events of pain and bleeding were noted. There were only four instances of dosimeter migration of >5 mm from known factors. A deviation of > or =7% in cumulative dose was noted in 7 of 36 (19%) for breast cancer patients. In prostate cancer patients, a > or =7% deviation was noted in 6 of 29 (21%) and 8 of 19 (42%) during initial and boost irradiation, respectively. The two patterns of dose deviation were random and systematic. Some causes for these differences could involve organ movement, patient movement, or treatment plan considerations.
The Dose Verification System was not associated with significant adverse events or migration. The dosimeter can measure dose in situ on a daily basis. The accuracy and utility of the dose verification system complements current image-guided radiation therapy and intensity-modulated radiation therapy techniques.

Download full-text


Available from: Bradley R. Prestidge, Feb 11, 2015
  • Source
    • "When the internal anatomy is difficult to see on the X-ray image, a fiducial marker may be implanted in the patient to aid in patient alignment. Since the DVS dosimeter is designed to be implanted in the patient, it has been suggested by Scarantino et al. and Beyer et al. [3], [4] that it could be used as a fiducial marker as well as a dosimeter. Furthermore, Kry et al. [5] found that the dosimeter could conceivably be used as a fiducial marker in IGRT using kilovoltage (kV) imaging. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In radiation therapy, the tumor and normal tissue response is highly dependent on accurate absorbed dose delivery to the intended target. Although ex vivo techniques are widely used to improve the accuracy of the dose delivered, it is impossible to verify that the dose has been delivered correctly without mea-suring the dose within the patient. The Dose Verification System (Sicel Technologies, Inc., Morrisville, NC), which consists of an im-plantable MOSFET dosimeter and a wireless reader, is currently the only commercial dosimetry system capable of measuring this in situ dose. Since the MOSFET dosimeter is implanted in the patient, it has been suggested that it could be used as not only a dosimeter but also a fiducial marker for image-guided radiation therapy (IGRT) provided that it could be seen on radiographs. Though visible on kilovoltage radiographs, the current design of the dosimeter is not visible on megavoltage radiographs limiting its usefulness in IGRT treatment. In this work, we modified the MOSFET dosimeter to increase its visibility on megavoltage radiographs. We then compared the visibility of the modified dosimeter with that of the commercial (unmodified) dosimeter and a traditional gold fiducial marker in an anthropomorphic phantom on an IGRT system. To ensure that the modification did not affect the dosimeter's ability to measure and transmit dose data, we compared the modified dosimeter's wireless read range, energy dependence, and angular dependence with those of the commercial dosimeter. We conclude that modifying the MOSFET dosimeter increased its visibility without affecting its dosimetric properties, thereby allowing a single implanted device to serve two critical roles in IGRT. Index Terms—Dose verification system, fiducial marker, image-guided radiation therapy (IGRT), in vivo dosimetry, MOSFET, quality assurance.
    IEEE Sensors Journal 10/2011; 11(10):2591-2597. DOI:10.1109/JSEN.2011.2144581 · 1.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nearly all public-key cryptographic algorithms are based on hard problems of number theory, which are related to each other. That is to say, if one of these algorithms is broken, the other's security will be threatened. This work presents a new public-key ciphering mechanism that isn't based on any of the classic cryptographical problems. The method consists of permuting the elements of the field GF(2<sup>L</sup>). The permutation is constructed by composition of bijective transitions based on the feedback functions of the feedback shift registers. The permutation algorithm is transmitted as a nonlinear equation system, where the difficulty of solving it conveys the security of the cipher. At the implementation level, the proposed scheme makes use of NLFSR (non-linear feedback shift registers), modifying the feedback function at each iteration. The resulting ciphering mechanism is able to generate any permutation
    Security Technology, 1999. Proceedings. IEEE 33rd Annual 1999 International Carnahan Conference on; 02/1999
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In highly-conformal radiotherapy, due to the complexity of both beam configurations and dose distributions, traditional in vivo dosimetry is unpractical or even impossible. The ideal dosimeter would be implanted inside the planning treatment volume so that it can directly measure the total delivered dose during each fraction with no additional uncertainty due to calculation models. The aim of this work is to verify if implantable metal oxide semiconductors field effect transistors (MOSFETs) can achieve a sufficient degree of dosimetric accuracy when used inside extracranial targets undergoing radiotherapy treatments using the Cyberknife system. Based on the preliminary findings of this study, new prototypes for high dose fractionations were developed to reduce the time dependence for long treatment delivery times. These dosimeters were recently cleared and are marketed as DVS-HFT. Multiple measurements were performed using both Virtual Water and water phantoms to characterize implantable MOSFETs under the Cyberknife beams, and included the reference-dosimetry consistency, the dependence of the response on the collimator size, on the daily delivered dose, and the time irradiation modality. Finally a Cyberknife prostate treatment simulation using a body phantom was conducted, and both MOSFET and ionization readings were compared to Monte Carlo calculations. The feasibility analysis was conducted based on the ratios of the absorbed dose divided by the dose reading, named as "further calibration factor" (FCF). The average FCFs resulted to be 0.98 for the collimator dependence test, and about 1.00 for the reference-dosimetry test, the dose-dependence test, and the time-dependence test. The average FCF of the prostate treatment simulation test was 0.99. The obtained results are well within DVS specifications, that is, the factory calibration is still valid for such kind of treatments using the Cyberknife system, with no need of further calibration factors to be applied. The final accuracy of implantable MOSFETs when used for such kind of treatments was estimated to be within +/- 4%. Additional investigations using dose/fraction higher than 12 Gy, different beam configurations, and tracking systems could extend the present findings to other kind of treatments. MOSFET technology was proven to have high versatility in fast adaptation of existing detectors to new applications. It is plausible to expect a general feasibility of implantable MOSFET technology for in vivo dosimetry of the extracranial-targets treatments using the Cyberknife, provided each particular application will be validated by suitable both physical and clinical studies.
    Medical Physics 04/2010; 37(4):1413-23. DOI:10.1118/1.3315370 · 3.01 Impact Factor
Show more